278. 巨大リンパ管奇形（頚部顔面病変） Disease details / Clinical trials / Drug dev / DR info

Alpelisib
   Murdoch Childrens Research Institute
      2024   Phase 2   NCT05983159   Australia
   Novartis Pharmaceuticals
      2023   Phase 2/Phase 3   NCT05948943   Australia;Belgium;France;Germany;Italy;Spain;United States
Bleomycin
   Fujino Akihiro
      2016   -   JPRN-jRCTs031180265   -
   West China Hospital
      2023   Phase 2   NCT06437158   China
CERC-006
   Cerecor Inc
      2021   Phase 1   NCT04994002   United States
Genetic profiling OF ALL eligible patients
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2024   -   NCT06892964   Italy
Indocyanine green
   Aitaro Takimoto
      2017   Phase 2   JPRN-jRCTs041190036   -
   Nagoya University Graduate School of Medicine
      2017   -   JPRN-UMIN000025845   Japan
Indocyanine green-guided partial resection and sclerotherapy
   Nanjing Children's Hospital
      2023   -   NCT06275022   China
Inflow occlusion with perforation OF septation and sclerotherapy
   Nanjing Children's Hospital
      2023   -   NCT06275022   China
L04aa10
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France
Mirdametinib
   Murdoch Childrens Research Institute
      2024   Phase 2   NCT05983159   Australia
OK432
   Richard JH Smith
      1998   Phase 4   NCT03427619   United States
Oral sirolimus
   Children's Hospital of Fudan University
      2021   Phase 4   NCT04921722   China
Percutaneous sirolimus
   Children's Hospital of Fudan University
      2021   Phase 4   NCT04921722   China
Picibanil
   University of Iowa
      2000   Phase 2/Phase 3   NCT00010452   United States
Polidocanol
   Mori Hiroki
      2024   Phase 2   JPRN-jRCTs031230604   Japan;Non
Propranolol
   University of Tokyo
      2012   Phase 2   JPRN-UMIN000008498   Japan
PTX-022
   Palvella Therapeutics, Inc.
      2022   Phase 2   NCT05050149   United States
Qtorin 3.9% rapamycin anhydrous GEL
   Palvella Therapeutics, Inc.
      2024   Phase 3   NCT06239480   United States
Rapamune
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France
   West China Hospital
      2024   Phase 2/Phase 3   NCT06673290   China
RLY-2608
   Relay Therapeutics, Inc.
      2025   Phase 2   NCT06789913   United States
Sclerotherapy with intralesional bleomycin injection
   National Children's Hospital, Vietnam
      2018   -   NCT06943703   Vietnam
Selenium
   Medical College of Wisconsin
      2010   Phase 1   NCT01212965   United States
Sildenafil
   Beijing Children's Hospital
      2014   -   ChiCTR-OPC-16008702   China
Sildenafil 20 MG tablets
   Stanford University
      2015   Phase 2   NCT02335242   United States
Sirolimus
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT00975819   United States
   Gifu University
      2017   -   JPRN-UMIN000030522   Japan
   Gifu University Hospital
      2020   Phase 3   JPRN-UMIN000038973   Japan
   Medical University of South Carolina
      2022   Phase 2   NCT04861064   United States
   West China Hospital
      2024   Phase 2/Phase 3   NCT06673290   China
Sirolimus 0,1% CRèME
   CHRU TOURS
      2019   Phase 2   EUCTR2018-001359-11-FR   France
Sirolimus 1MG oral tablet
   Sohag University
      2023   -   NCT06160739   Egypt
Sirolimus 1MG/ML
   CHRU TOURS
      2019   Phase 2   EUCTR2019-001530-33-FR   France
Sirolimus oral liquid product 1MG/ML
   University Hospital, Tours
      2020   Phase 2   NCT04128722   France
TARA-002
   Protara Therapeutics
      2023   Phase 2   NCT05871970   United States
Topical 0.1% sirolimus
   University Hospital, Tours
      2019   Phase 2   NCT03972592   France
Topical vehicle
   University Hospital, Tours
      2019   Phase 2   NCT03972592   France
Water
   Fujino Akihiro
      2016   -   JPRN-jRCTs031180265   -